Vimarsana
Biggest News Aggregation in the World

Page 9 - Alanh Auerbach News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alanh Auerbach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alanh Auerbach Today - Breaking & Trending Today

Puma Biotechnology Reports Second Quarter 2022 Financial Results - Vimarsana News

Puma Biotechnology Reports Second Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Unless otherwise stated, all comparisons are for the second quarter of 2022 compared to the second quarter of 2021.Product revenue, net consists...

Dupont Capital Management Corp Sells 5,770 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Vimarsana News

Dupont Capital Management Corp Sells 5,770 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Puma Biotechnology Reports First Quarter 2022 Financial Results - Vimarsana News

Puma Biotechnology Reports First Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022. Unless otherwise stated, all comparisons are for the first quarter of 2022 compared to the first quarter of 2021.Product revenue, net consists en...

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results - Vimarsana News

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Puma Biotechnology : Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting - Vimarsana News

Puma Biotechnology : Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting

Dose escalation of neratinib lowers the frequency of severe diarrhea and improves overall tolerability in patients with HER2-positive early stage breast cancer ... | June 4, 2021